| Literature DB >> 26668602 |
Yafen Cheng1, Chung-Hsi Chou2, Hsiang-Jung Tsai3.
Abstract
The intracellular parasite Mycobacterium bovis (M. bovis) causes tuberculosis in cattle and humans. Understanding the interactions between M. bovis and host cells is essential in developing tools for the prevention, detection, and treatment of M. bovis infection. Gene expression profiles provide a large amount of information regarding the molecular mechanisms underlying these interactions. The present study analyzed changes in gene expression in bovine peripheral blood mononuclear cells (PBMCs) at 0, 4 and 24 h following exposure to M. bovis. Using bovine whole-genome microarrays, a total of 420 genes were identified that exhibited significant alterations in expression (≥2-fold). Significantly enriched genes were identified using the Kyoto Encyclopedia of Genes and Genomes database, of which the highest differentially expressed genes were associated with the immune system, signal transduction, endocytosis, cellular transport, inflammation, and apoptosis. Of the genes associated with the immune system, 84.85% displayed downregulation. These findings support the view that M. bovis inhibits signaling pathways of antimycobacterial host defense in bovine PBMCs. These in vitro data demonstrated that molecular alterations underlying the pathogenesis of tuberculosis begin early, during the initial 24 h following M. bovis infection.Entities:
Keywords: Mycobacterium bovis; global gene expression; immune response; macrophage
Year: 2015 PMID: 26668602 PMCID: PMC4665668 DOI: 10.3892/etm.2015.2814
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1.Significantly differentially expressed genes at each time point following Mycobacterium bovis challenge of peripheral blood mononuclear cells. The number of upregulated and downregulated genes relative to uninfected controls are shown for each time point sampled. *Adjusted P≤0.05.
Genes with upregulated expression (≥2.5-fold) following exposure of peripheral blood mononuclear cells to Mycobacterium bovis.
| Fold change | ||||||
|---|---|---|---|---|---|---|
| Processes | Symbol | 0–4 h | 4–24 h | 0–24 h | P-value | Gene name |
| Signal transduction | ||||||
| CLEC4E | 1.15 | 7.70 | 8.85 | 0.001 | C-type lectin domain family 4 member E | |
| STAT1 | 0.71 | 2.98 | 2.12 | 0.002 | Signal transducer and activator of transcription 1 | |
| DDIT3 | 0.78 | 2.91 | 2.27 | 0.004 | DNA-damage-inducible transcript 3 | |
| LDHA | 0.77 | 2.81 | 2.16 | <0.001 | Lactate dehydrogenase A (LDHA) | |
| Immune system | ||||||
| C3AR1 | 0.97 | 6.68 | 6.49 | 0.002 | Complement component 3a receptor 1 | |
| PDK1 | 0.86 | 6.14 | 5.26 | 0.001 | Pyruvate dehydrogenase kinase, isozyme 1 | |
| DAPP1 | 0.58 | 4.16 | 2.43 | <0.001 | Dual adaptor of phosphotyrosine and 3-phosphoinositides | |
| RASGRP1 | 0.90 | 3.43 | 3.09 | <0.001 | RAS guanyl releasing protein 1 (calcium and DAG-regulated) | |
| CD244 | 0.94 | 3.29 | 3.08 | <0.001 | CD244 molecule, natural killer cell receptor 2B4 | |
| IL7 | 0.61 | 2.63 | 1.59 | 0.001 | Interleukin-7 precursor | |
| Endocytosis and transport | ||||||
| COLEC11 | 1.14 | 4.78 | 5.44 | <0.001 | Collectin sub-family member 11 | |
| LAMP3 | 0.97 | 2.81 | 2.72 | 0.001 | Lysosomal-associated membrane protein 3 | |
| CTSL2 | 0.39 | 2.78 | 1.08 | 0.005 | Cathepsin L2 | |
| EHD1 | 0.90 | 2.58 | 2.33 | 0.001 | EH-domain containing 1 | |
| Inflammation and apoptosis | ||||||
| CDKN2D | 1.21 | 03.15 | 3.82 | <0.001 | Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) | |
| CCNG2 | 0.59 | 2.60 | 1.53 | 0.004 | Cyclin G2 | |
| Others | ||||||
| ME1 | 0.95 | 6.79 | 6.48 | 0.002 | Malic enzyme 1 | |
| FBXL3 | 0.90 | 4.21 | 3.80 | <0.001 | F-box and leucine-rich repeat protein 3 | |
| SQLE | 0.97 | 3.52 | 3.41 | 0.003 | Squalene epoxidase | |
| POLD4 | 1.01 | 3.34 | 3.37 | 0.003 | Polymerase (DNA-directed), delta 4 | |
| PTGES | 1.12 | 3.13 | 3.52 | <0.001 | Prostaglandin E synthase (PTGES) | |
| PHOSPHO2 | 1.03 | 3.06 | 3.15 | <0.001 | Phosphatase, orphan 2 | |
| DCK | 1.03 | 2.99 | 3.07 | <0.001 | Deoxycytidine kinase | |
| PLA2G16 | 0.84 | 2.91 | 2.44 | <0.001 | Phospholipase A2, group XVI | |
| CSGALNACT1 | 1.07 | 2.87 | 3.07 | 0.001 | Chondroitisulfate N-acetylgalactosam inyltransferase 1 | |
| NAPB | 0.85 | 2.83 | 2.40 | 0.005 | N-ethylmaleimide-sensitive factor attachment protein, beta | |
| PGAP1 | 1.00 | 2.77 | 2.76 | <0.001 | Similar to GPI deacylase | |
| HSD17B7 | 0.93 | 2.65 | 2.47 | 0.002 | Hydroxysteroid (17-beta) dehydrogenase 7 | |
| TRIP10 | 1.05 | 2.63 | 2.75 | <0.001 | Thyroid hormone receptor interactor 10 | |
| FDFT1 | 0.92 | 2.62 | 2.41 | <0.001 | Farnesyl-diphosphate farnesyltransferase 1 | |
Fold change was calculated as the mean of triplicate experiments.
Genes with downregulated expression (≥ 2.5-fold) following exposure of peripheral blood mononuclar cells to Mycobacterium bovis.
| Fold change | ||||||
|---|---|---|---|---|---|---|
| Processes | Symbol | 0–4 h | 4–24 h | 0–24 h | P-value | Gene name |
| Signal transduction | ||||||
| THBS1 | 1.33 | −27.82 | −20.91 | <0.001 | Thrombospondin 1 | |
| HMOX1 | 1.29 | −10.11 | −7.86 | <0.001 | Heme oxygenase (decycling) 1 | |
| FST | 1.19 | −7.82 | −6.59 | <0.001 | Follistatin | |
| FOSL1 | −1.08 | −5.65 | −6.11 | 0.004 | Fos-related antigen 1 (FRA-1) | |
| CD38 | 1.05 | −5.64 | −5.38 | 0.002 | CD38 molecule | |
| GNG4 | 1.06 | −5.21 | −4.93 | <0.001 | Guanine nucleotide binding protein (G protein), gamma 4 | |
| FZD4 | 1.20 | −4.98 | −4.16 | <0.001 | Frizzled homolog 4 | |
| EDN1 | −1.14 | −4.51 | −5.13 | 0.002 | Endothelin 1 | |
| PTAFR | 1.14 | −4.01 | −3.51 | 0.005 | Platelet-activating factor receptor | |
| MRAS | 1.29 | −3.64 | −2.82 | 0.002 | Muscle RAS oncogene homolog | |
| FOS | −1.02 | −3.56 | −3.64 | 0.002 | FBJ murine osteosarcoma viral oncogene homolog | |
| ICOS | −1.30 | −3.06 | −3.99 | <0.001 | Inducible T-cell co-stimulator | |
| FN1 | 1.20 | −2.87 | −2.40 | 0.004 | Fibronectin 1 | |
| NUMBL | 1.24 | −2.83 | −2.28 | 0.002 | Numb homolog (Drosophila)-like | |
| CACNG4 | 1.25 | −2.79 | −2.24 | 0.001 | Calcium channel, voltage-dependent, gamma subunit 4 | |
| PTGS2 | −1.13 | −2.71 | −3.06 | <0.001 | Prostaglandin-endoperoxide synthase 2 | |
| TCF7L2 | 1.21 | −2.51 | −2.08 | <0.001 | Transcription factor 7-like 2 (T-cell specific, HMG-box) | |
| Immune system | ||||||
| C1QB | 1.21 | −26.31 | −21.76 | 0.002 | Complement component 1, q subcomponent, B chain | |
| PPBP | −1.07 | −17.11 | −18.37 | <0.001 | Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) | |
| CFB | −1.07 | −16.33 | −17.52 | <0.001 | Complement factor B (CFB) | |
| IFNG | 1.02 | −14.28 | −14.06 | <0.001 | Interferon, gamma | |
| THBD | −1.00 | −14.27 | −14.32 | <0.001 | Thrombomodulin | |
| GZMB | 1.13 | −9.25 | −8.21 | <0.001 | Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | |
| C1QA | 1.08 | −7.58 | −7.03 | <0.001 | Complement component 1, q subcomponent, A chain | |
| SPP1 | −1.07 | −6.62 | −7.05 | 0.003 | Secreted phosphoprotein 1 | |
| PLK3 | −1.10 | −5.99 | −6.60 | <0.001 | Polo-like kinase 3 (Drosophila) | |
| F13A1 | 1.07 | −5.12 | −4.79 | 0.002 | Coagulation factor XIII, A1 polypeptide | |
| PLA2G4A | 1.07 | −4.58 | −4.28 | 0.002 | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | |
| CD55 | −1.09 | −4.54 | −4.97 | <0.001 | CD55 molecule, decay accelerating factor for complement (Cromer blood group) | |
| CD14 | 1.49 | −4.41 | −2.96 | <0.001 | CD14 molecule | |
| IL10 | −1.29 | −4.11 | 5.30 | 0.002 | Interleukin 10 | |
| MAP3K8 | −1.17 | −4.02 | −4.70 | <0.001 | Mitogen-activated protein kinase kinase kinase 8 | |
| CCR3 | 1.01 | −3.88 | −3.84 | 0.003 | Chemokine (C-C motif) receptor 3 | |
| CCR4 | −1.06 | −3.63 | −3.85 | 0.002 | Chemokine (C-C motif) receptor 4 | |
| KLRK1 | −1.16 | −3.55 | −4.12 | <0.001 | Killer cell lectin-like receptor subfamily K, member 1 | |
| IL2RA | −1.00 | −3.46 | −3.48 | <0.001 | Interleukin 2 receptor, alpha (IL2RA) | |
| CSF1R | 1.32 | −3.41 | −2.58 | <0.001 | Colony stimulating factor 1 receptor precursor | |
| CCR1 | 1.08 | −3.18 | −2.95 | 0.003 | Chemokine (C-C motif) receptor 1 | |
| CCL4 | −1.06 | −3.13 | −3.31 | 0.006 | Chemokine (C-C motif) ligand 4 (CCL4), | |
| INHBA | 1.04 | −3.13 | −3.02 | 0.002 | Inhibin, beta A | |
| PECAM1 | 1.04 | −3.59 | −3.47 | 0.001 | Platelet/endothelial cell adhesion molecule | |
| TNFRSF25 | −1.10 | −3.08 | −3.40 | <0.001 | Tumor necrosis factor receptor superfamily, member 25 | |
| CCL3 | 1.35 | −3.01 | −2.22 | 0.002 | Chemokine (C-C motif) ligand 3 | |
| TLR8 | −1.26 | −2.85 | −3.60 | 0.006 | Toll-like receptor 8 | |
| IL12B | −1.20 | −2.83 | −3.40 | 0.004 | Interleukin 12B | |
| CTSB | −1.06 | −2.79 | −2.97 | 0.003 | Cathepsin B | |
| JAM3 | 1.05 | −2.67 | −2.54 | <0.001 | Junctional adhesion molecule 3 | |
| SIPA1 | 1.07 | −2.61 | −2.43 | 0.003 | Signal-induced proliferation-associated 1 | |
| PGD | −1.16 | −2.54 | −2.95 | 0.004 | Phosphogluconate dehydrogenase | |
| Endocytosis and transport | ||||||
| RAB7B | 1.13 | −4.29 | −3.79 | <0.001 | RAB7B, member RAS oncogene family | |
| CD36 | 1.02 | −3.58 | −3.50 | 0.001 | CD36 molecule (thrombospondin receptor) | |
| ACP2 | 1.00 | −3.56 | −3.54 | <0.001 | Acid phosphatase 2, lysosomal | |
| SORT1 | −1.02 | −3.45 | −3.51 | <0.001 | Sortilin 1 | |
| ACTB | 1.17 | −2.85 | −2.44 | <0.001 | Actin, beta | |
| AP1B1 | 1.03 | −2.78 | −2.71 | <0.001 | Adaptor-related protein complex 1, beta 1 subunit | |
| Inflammation and apoptosis | ||||||
| TNF | −1.02 | −6.07 | −6.18 | <0.001 | Tumor necrosis factor (TNF superfamily, member 2) | |
| IL1RAP | 1.17 | −4.85 | −5.67 | 0.005 | Interleukin 1 receptor accessory protein | |
| IGFBP3 | −1.06 | −3.06 | −3.23 | 0.002 | Insulin-like growth factor binding protein 3 | |
| CDKN1C | 1.33 | −2.95 | −2.22 | <0.001 | Cyclin-dependent kinase inhibitor 1C (p57, Kip2) | |
| AMOTL1 | −1.10 | −2.71 | −2.99 | 0.001 | Angiomotin like 1 | |
| FASLG | −1.19 | −2.62 | 3.12 | <0.001 | Fas ligand | |
| Others | ||||||
| CYP3A4 | −1.04 | −4.65 | −4.83 | 0.002 | Cytochrome P450, subfamily IIIA, polypeptide 4 | |
| B4GALT6 | −1.05 | −4.09 | −4.31 | 0.003 | B4GALT6 protein, transcript variant 2 | |
| TBXAS1 | 1.07 | −4.03 | −3.78 | 0.002 | Thromboxane A synthase 1 | |
| ST8SIA1 | 1.07 | −3.78 | 3.52 | 0.002 | Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase | |
| GAB1 | 1.29 | −3.61 | −4.65 | <0.001 | GRB2-associated binding protein 1 | |
| HSD17B8 | 1.01 | −3.60 | −3.57 | 0.005 | Hydroxysteroid (17-beta) dehydrogenase 8 | |
| HS3ST1 | 1.55 | −3.27 | −2.11 | 0.001 | Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 | |
| MMP14 | 1.04 | −3.09 | −2.96 | <0.001 | Matrix metallopeptidase 14 | |
| ITGAD | 1.03 | −2.83 | −2.75 | <0.001 | Integrin, alpha D | |
| TXNDC5 | −1.08 | −3.34 | −3.60 | <0.001 | Thioredoxin domain-containing protein 5 precursor | |
| VIM | 1.06 | −2.59 | −2.44 | 0.004 | Vimentin | |
| SDS | −1.23 | −3.93 | −4.85 | <0.001 | Serine dehydratase | |
| EME2 | 1.09 | −2.65 | 2.44 | 0.003 | Endonuclease | |
| SFRS7 | −1.02 | −2.82 | −2.87 | <0.001 | Splicing factor, arginine/serine-rich 7 | |
| NUP160 | 1.15 | −3.01 | −2.62 | 0.001 | Nucleoporin 160kDa | |
| PWP2 | 1.13 | −2.92 | −2.59 | <0.001 | Periodic tryptophan protein 2 homolog | |
| DSE | −1.09 | −2.92 | −3.17 | <0.001 | Dermatan sulfate epimerase | |
| PNPLA4 | 1.10 | −2.83 | −2.57 | <0.001 | Patatin-like phospholipase domain containing 4 | |
| BLVRB | 1.00 | −2.75 | −2.75 | <0.001 | Biliverdin reductase B | |
| CHST2 | 1.04 | −2.75 | −2.64 | <0.001 | Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 | |
| AGPAT3 | 1.08 | −2.63 | −2.43 | <0.001 | 1-acylglycerol-3-phosphate O-acyltransferase 3 | |
| EXT1 | −1.19 | −2.61 | −3.12 | 0.001 | Exostoses (multiple) 1 | |
| GSTK1 | 1.12 | −2.60 | −2.90 | 0.002 | Glutathione S-transferase kappa 1 | |
Fold change was calculated as the mean of triplicate experiments.
Figure 2.Profile of differentially expressed genes organized by functional subcategories of Kyoto Encyclopedia of Genes and Genomes pathways. Based on the number of genes with altered expression, Mycobacterium bovis exposure had the greatest effect on genes associated with the immune response.
Ingenuity pathway analysis profile of genes differentially expressed between 0 and 4 hours post-infection with Mycobacterium bovis.
| Symbol | Entrez gene name | Fold change | Network | Location | Type(s) |
|---|---|---|---|---|---|
| CLDN3 | Claudin 3 | 3.07 | 3 | Plasma membrane | Transmembrane receptor |
| MMP2 | Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) | 0.11 | 3 | Extracellular space | Peptidase |
| MAPK14 | Mitogen-activated protein kinase 14 | 0.05 | 1 | Cytoplasm | Kinase |
| GEMIN6 | Gem (nuclear organelle) associated protein 6 | −0.09 | 4 | Nucleus | Other |
| TNF | Tumor necrosis factor | −0.09 | 1 | Extracellular space | Cytokine |
| TGFB1 | Transforming growth factor, beta 1 | −0.13 | 1 | Extracellular space | Growth factor |
| CREB1 | cAMP responsive element binding protein 1 | −0.51 | Nucleus | Transcription regulator | |
| IL1B | Interleukin 1, beta | −0.52 | 1 | Extracellular space | Cytokine |
| STRAP | Serine/threonine kinase receptor associated protein | −0.60 | 4 | Plasma membrane | Other |
| REM1 | RAS (RAD and GEM)-like GTP-binding 1 | −3.13 | Other | Enzyme | |
| MMP13 | Matrix metallopeptidase 13 (collagenase 3) | −6.25 | 1 | Extracellular space | Peptidase |
| ADCY6 | Adenylate cyclase 6 | −6.67 | 2 | Plasma membrane | Enzyme |
| GEMIN7 | Gem (nuclear organelle) associated protein 7 | −11.11 | 4 | Nucleus | Other |
| SMURF2 | SMAD specific E3 ubiquitin protein ligase 2 | −16.67 | 1 | Cytoplasm | Enzyme |
| FMO4 | Flavin containing monooxygenase 4 | −32.98 | Cytoplasm | Enzyme |
Pathways involving genes differentially expressed between 0 and 4 hours post-infection with Mycobacterium bovis.
| Ingenuity canonical pathway | |−log (p)| | Gene ratio[ | Genes |
|---|---|---|---|
| Granulocyte adhesion and diapedesis | 2.57 | 1.2E-02 | MMP13, CLDN3 |
| Agranulocyte adhesion and diapedesis | 2.52 | 1.14E-02 | MMP13, CLDN3 |
| Leukocyte extravasation signaling | 2.43 | 1.02E-02 | MMP13, CLDN3 |
| Oncostatin M signaling | 1.78 | 2.94E-02 | MMP13 |
| Inhibition of matrix metalloproteases | 1.73 | 2.63E-02 | MMP13 |
| CDK5 signaling | 1.38 | 1.12E-02 | ADCY6 |
| TGF-β signaling | 1.38 | 1.08E-02 | SMURF2 |
| IL-1 signaling | 1.36 | 9.8E-03 | ADCY6 |
| HIF1α signaling | 1.32 | 9.8E-03 | MMP13 |
| Gαi signaling | 1.24 | 7.81E-03 | ADCY6 |
| eNOS signaling | 1.23 | 7.75E-03 | ADCY6 |
| CXCR4 signaling | 1.15 | 6.25E-03 | ADCY6 |
| Gap junction signaling | 1.15 | 6.41E-03 | ADCY6 |
| Tight junction signaling | 1.14 | 6.37E-03 | CLDN3 |
| PPARα/RXRα activation | 1.11 | 5.75E-03 | ADCY6 |
| RAR activation | 1.09 | 5.59E-03 | ADCY6 |
| LPS/IL-1 mediated inhibition of RXR function | 1.01 | 4.5E-03 | FMO4 |
Number of pathway genes differentially expressed/number of genes in pathway.
Ingenuity pathway analysis profile of genes differentially expressed between 0 and 24 hours post-infection with Mycobacterium bovis.
| Symbol | Entrez gene name | Fold change | Network | Location | Type(s) |
|---|---|---|---|---|---|
| GPNMB | Glycoprotein (transmembrane) nmb | 22.93 | 2 | Plasma membrane | Enzyme |
| AK4 | Adenylate kinase 4 | 19.13 | 4 | Cytoplasm | Kinase |
| KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | 18.27 | 4 | Plasma membrane | Ion channel |
| CLEC4E | C-type lectin domain family 4, member E | 13.36 | 2 | Plasma membrane | Other |
| CLU | Clusterin | 12.13 | 4 | Cytoplasm | Other |
| C3AR1 | Complement component 3a receptor 1 | 7.93 | 1 | Plasma membrane | G-protein coupled receptor |
| Akt | Bos taurus v-akt murine thymoma viral oncogene homolog 2 | 2.06 | 4 | Cytoplasm | Group |
| BCL2 | B-cell CLL/lymphoma 2 | −0.29 | 3 | Cytoplasm | Transporter |
| CASP8 | Caspase 8, apoptosis-related cysteine peptidase | −0.60 | Nucleus | Peptidase | |
| NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | −0.80 | Nucleus | Transcription regulator | |
| IL1B | Interleukin 1, beta | −1.04 | Extracellular space | Cytokine | |
| FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | −1.98 | Plasma membrane | Transmembrane receptor | |
| CD55 | CD55 molecule, decay accelerating factor for complement (Cromer blood group) | −4.76 | 2 | Plasma membrane | Other |
| TNF | Tumor necrosis factor | −6.45 | 1 | Extracellular space | Cytokine |
| C1QA | Complement component 1, q subcomponent, A chain | −7.69 | 1 | Extracellular space | Other |
| PLK3 | Polo-like kinase 3 | −8.33 | 3 | Nucleus | Kinase |
| CEBPD | CCAAT/enhancer binding protein (C/EBP), delta | −9.09 | 4 | Nucleus | Transcription regulator |
| IL17F | Interleukin 17F | −9.52 | 1 | Extracellular space | Cytokine |
| GZMB | Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | −11.11 | 1 | Cytoplasm | Peptidase |
| MMP13 | Matrix metallopeptidase 13 (collagenase 3) | −11.11 | 1 | Extracellular space | Peptidase |
| SMURF2 | SMAD specific E3 ubiquitin protein ligase 2 | −12.50 | 3 | Cytoplasm | Enzyme |
| CFB | Complement factor B | −13.33 | 1 | Extracellular space | Peptidase |
| THBS1 | Thrombospondin 1 | −13.33 | 1,2 | Extracellular space | Other |
| FMO4 | Flavin containing monooxygenase 4 | −14.29 | Cytoplasm | Enzyme | |
| IFNG | Interferon, gamma | −20.00 | 1,3 | Extracellular space | Cytokine |
| THBD | Thrombomodulin | −20.00 | 1 | Plasma membrane | Transmembrane receptor |
| IL17RB | Interleukin 17 receptor B | −25.00 | 1 | Plasma membrane | Transmembrane receptor |
| C1QB | Complement component 1, q subcomponent, B chain | −28.57 | 1 | Extracellular space | Other |
Pathways involving genes differentially expressed between 0 and 24 hours post-infection with Mycobacterium bovis.
| Ingenuity canonical pathways | |-log (P)| | Gene ratio[ | Molecules |
|---|---|---|---|
| Pattern recognition receptors in recognition of bacteria and viruses | 3.23E00 | 4.21E-02 | C1QA, C1QB, C3AR1, TNF |
| Production of nitric oxide and reactive oxygen species in macrophages | 3.02E00 | 2.69E-02 | IFNG, MAP3K8, TNF, CLU, RBP4 |
| Cytokines mediating communication between immune cells | 2.86E00 | 5.77E-02 | IFNG, IL17F, TNF |
| T helper cell differentiation | 2.55E00 | 4.35E-02 | IFNG, IL17F, TNF |
| VDR/RXR activation | 2.37E00 | 3.85E-02 | IFNG, SPP1, THBD |
| Crosstalk between dendritic cells and natural killer cells | 2.2E00 | 3.3E-02 | IFNG, TNF, ACTG1 |
| Acute phase response signaling | 1.47E00 | 1.73E-02 | CFB, TNF, RBP4 |
| Communication between innate and adaptive immune cells | 1.33E00 | 2.15E-02 | IFNG, TNF |
| PI3K/AKT signaling | 1.03E00 | 1.48E-02 | GAB1, MAP3K8 |
| TNFR2 signaling | 9.51E-01 | 3.12E-02 | TNF |
| Interferon signaling | 8.72E-01 | 2.94E-02 | IFNG |
| Antigen presentation pathway | 8.38E-01 | 2.5E-02 | IFNG |
| Inhibition of matrix metalloproteases | 8.28E-01 | 2.63E-02 | MMP13 |
| NF-κB signaling | 7.96E-01 | 1.14E-02 | MAP3K8, TNF |
| iNOS signaling | 7.78E-01 | 2.13E-02 | IFNG |
| TNFR1 signaling | 7.43E-01 | 1.96E-02 | TNF |
| Cytotoxic T lymphocyte-mediated apoptosis of target cells | 7.27E-01 | 1.92E-02 | GZMB |
| Leukocyte extravasation signaling | 7.08E-01 | 1.02E-02 | MMP13, ACTG1 |
| Death receptor signaling | 6.62E-01 | 1.61E-02 | TNF |
| Activation of IRF by cytosolic pattern recognition receptors | 6.49E-01 | 1.59E-02 | TNF |
| Role of PI3K/AKT signaling in the pathogenesis of influenza | 6.42E-01 | 1.49E-02 | IFNG |
| IL-10 signaling | 6.01E-01 | 1.39E-02 | TNF |
| Apoptosis signaling | 5.06E-01 | 1.09E-02 | TNF |
| Fcγ receptor-mediated phagocytosis in macrophages and monocytes | 4.87E-01 | 1.05E-02 | ACTG1 |
Number of pathway genes differentially expressed/number of genes in pathway.
Figure 3.Network 1 of pathways involving genes differentially expressed between 0 and 4 h post-infection with Mycobacterium bovis.
Figure 6.Network 4 of pathways involving genes differentially expressed between 0 and 4 h post-infection with Mycobacterium bovis.
Figure 4.Network 2 of pathways involving genes differentially expressed between 0 and 4 h post-infection with Mycobacterium bovis.
Figure 5.Network 3 of pathways involving genes differentially expressed between 0 and 4 h post-infection with Mycobacterium bovis.
Figure 7.Network 1 of pathways involving genes differentially expressed between 0 and 24 h post-infection with Mycobacterium bovis.
Figure 10.Network 4 of pathways involving genes differentially expressed between 0 and 24 h post-infection with Mycobacterium bovis.
Figure 8.Network 2 of pathways involving genes differentially expressed between 0 and 24 h post-infection with Mycobacterium bovis.
Figure 9.Network 3 of pathways involving genes differentially expressed between 0 and 24 h post-infection with Mycobacterium bovis.